CCR4 and mature T-cell and NK-cell non-Hodgkin lymphoma: Elevated CCR4 expression was also reported in patients with aggressive PTCL, especially in ATLL or CTCL; therefore, CCR4 seems to be a promising therapeutic target for T cell malignancies [72].